anti-neuropilin-1 antibody (Cygnal Therapeutics/Adimab)
N/A
Report date: 2025/03/18 18:10:18
Base Information
Drug Nameanti-neuropilin-1 antibody (Cygnal Therapeutics/Adimab)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCygnal Therapeutics
China Registration ClassN/A
Develop Information
Active CompaniesCygnal TherapeuticsAdimab LLC
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A